Neon Therapeutics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$261M
Industry:Biotech
Founded:2015
Lead Investor(s):Partner Fund Management
Press
Claim your profile

Industry Ranking

Estimated Revenue & Financials

  • Neon Therapeutics's estimated annual revenue is currently $14.1M per year.
  • Neon Therapeutics received $36.0M in venture funding in December 2017.
  • Neon Therapeutics's estimated revenue per employee is $111,063
  • Neon Therapeutics's total funding is $261M.

Employee Data

  • Neon Therapeutics has 127 Employees.
  • Neon Therapeutics grew their employee count by 0% last year.
  • Neon Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ultivue
$8.7M56-12%N/A
Ohana Bioscienc...
$8.7M5660%N/A
Compass Therape...
$16.4M10614%N/A
Cell Signaling ...
$89.4M577N/AN/A
Momenta Pharmac...
N/A220N/AN/A
Emulate
$15.3M99-17%N/A
ArQule
N/A94N/AN/A
Hamilton Storag...
$17.2M1119%N/A
Alnylam Pharmac...
$74.9M127731%N/A
Transgenomic
N/A47N/AN/A
Missing a competitor? Contribute!?
Submit

Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. For more information, please visit www.neontherapeutics.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

127

Number of Employees

$14.1M

Revenue (est)

1

Current Jobs

0%

Employee Growth %

$261M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Marc WolfgangVP, Technical OperationsEmail Available
Richard GaynorPresident, Research And Development
Zach TaylorSenior Director, Business Development and Strategy
Seth HarmonSenior Director Of Finance And AccountingEmail Available
Kerry ChiosAssociate DirectorEmail Available
Todd KenneyHead Of Quality, Senior Director Quality Assurance Email Available
Kathryn LandesDirector Gmp QaEmail Available
John CurranDirector, Sequencing OperationsEmail Available
Karyn HoffmanExecutive Assistant To The Chief Executive OfficerEmail Available
Yasir Al-WakeelCFOEmail Available

Neon Therapeutics News

09/03/2019 - Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens.

09/08/2019 - Neon Therapeutics up 14% premarket on data supporting MAPTAC technology

Thinly traded nano cap Neon Therapeutics (NASDAQ:NTGN) is up 14% premarket on average volume in response to a just-published paper in ...

09/03/2019 - Analysts Expect Neon Therapeutics (NTGN) Stock to Rise 310%; Rated Strong Buy

Neon Therapeutics Inc (NTGN) stock has fallen -66.87% over the last 12 months, and the average rating from Wall Street analysts is a Strong ...

Neon Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-10-02$55.0MAThird Rock VenturesArticle
2017-01-06$70.0MBPartner Fund ManagementArticle
2017-12-06$36.0MBArticle

Neon Therapeutics Executive Hires

DateNameTitleReference
2016-09-28Hugh O?DowdCEOArticle
2016-11-08Richard GaynorPres Research & DevelopmentArticle
2017-06-19Yasir Al-WakeelChief Financial OfficerArticle
2017-08-16Teresa ReganVP Human ResourcesArticle